NZ334870A - Bioconjugates having a bioactive agent and an organocobalt complex for to specific sites - Google Patents
Bioconjugates having a bioactive agent and an organocobalt complex for to specific sitesInfo
- Publication number
- NZ334870A NZ334870A NZ334870A NZ33487097A NZ334870A NZ 334870 A NZ334870 A NZ 334870A NZ 334870 A NZ334870 A NZ 334870A NZ 33487097 A NZ33487097 A NZ 33487097A NZ 334870 A NZ334870 A NZ 334870A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bioactive agent
- organocobalt complex
- bioconjugates
- organocobalt
- complex
- Prior art date
Links
- 239000012867 bioactive agent Substances 0.000 title abstract 6
- -1 and the like) Substances 0.000 abstract 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 238000006303 photolysis reaction Methods 0.000 abstract 2
- 230000015843 photosynthesis, light reaction Effects 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 108010002913 Asialoglycoproteins Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000018721 Macroglobulins Human genes 0.000 abstract 1
- 108010091934 Macroglobulins Proteins 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 102000013275 Somatomedins Human genes 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229910017052 cobalt Inorganic materials 0.000 abstract 1
- 239000010941 cobalt Substances 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 239000005515 coenzyme Substances 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 230000001443 photoexcitation Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
- 108010083117 tyrosyl(glutamyl)glutamate tris(N-acetylgalactosamineaminohexylglycoside)amide Proteins 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2503696P | 1996-08-27 | 1996-08-27 | |
| US2443096P | 1996-08-27 | 1996-08-27 | |
| PCT/US1997/014140 WO1998008859A1 (en) | 1996-08-27 | 1997-08-22 | Bioconjugates and delivery of bioactive agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334870A true NZ334870A (en) | 2000-12-22 |
Family
ID=26698439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334870A NZ334870A (en) | 1996-08-27 | 1997-08-22 | Bioconjugates having a bioactive agent and an organocobalt complex for to specific sites |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US6315978B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1007533B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2001501596A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE298344T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU738431B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2264592C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69733618T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2244006T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ334870A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1007533E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998008859A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739313A (en) * | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
| US6806363B1 (en) | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
| JP2002542207A (ja) * | 1999-04-16 | 2002-12-10 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | 抗腫瘍剤として有用なコバラミンコンジュゲート |
| MXPA02003772A (es) | 1999-10-15 | 2005-04-28 | Mayo Foundation | Conjugados de cobalamina, utiles como agentes para obtencion de imagen y como agentes terapeuticos. |
| US7591995B2 (en) | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
| AU4243400A (en) * | 1999-10-15 | 2001-04-30 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging agents and as antitumor agents |
| US7067111B1 (en) | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| US6797521B2 (en) | 1999-10-26 | 2004-09-28 | University Of Utah Research Foundation | Fluorescent cobalamins and uses thereof |
| DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
| US20020042394A1 (en) * | 2000-05-31 | 2002-04-11 | Hogenkamp Henricus P.C. | Cobalamin compounds useful as antibiotic agents and as imaging agents |
| AU6972901A (en) * | 2000-05-31 | 2001-12-11 | Mayo Foundation | Cobalamin compounds useful as cardiovascular agents and as imaging agents |
| IL153218A0 (en) | 2000-06-02 | 2003-07-06 | Univ Texas | Ethylenedicysteine (ec) -drug conjugates |
| TWI228512B (en) * | 2000-10-25 | 2005-03-01 | Mayo Foundation | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| EP1754712A3 (en) * | 2000-10-25 | 2009-01-14 | Mayo Foundation For Medical Education And Research | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| DE60117043T2 (de) * | 2000-11-22 | 2006-07-13 | Rxkinetix, Inc., Louisville | Behandlung von mukositis |
| WO2002076394A2 (en) * | 2001-03-22 | 2002-10-03 | The Ohio State University Research Foundation | Enzyme-based anti-cancer compositions and methods |
| US6752986B2 (en) * | 2001-05-24 | 2004-06-22 | The Cleveland Clinic Foundation | Composition and methods for affecting metallocorrinoid uptake |
| US20030031627A1 (en) | 2001-07-31 | 2003-02-13 | Mallinckrodt Inc. | Internal image antibodies for optical imaging and therapy |
| CA2461705A1 (en) * | 2001-09-28 | 2003-04-03 | Mayo Foundation For Medical Education And Research | Coadministration of transport protein with conjugated cobalamin to deliver agents |
| US6679827B2 (en) | 2001-10-11 | 2004-01-20 | Robert E. Sandstrom | Magnetic field enhancement of tumor treatment |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20040047917A1 (en) * | 2002-09-06 | 2004-03-11 | Stephen Wilson | Drug delivery and targeting with vitamin B12 conjugates |
| US7627373B2 (en) | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
| US20080138280A1 (en) * | 2003-02-20 | 2008-06-12 | The Cleveland Clinic Foundation | Composition and Methods For Inhibiting Cell Survival |
| US7232805B2 (en) * | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
| US7119065B2 (en) * | 2003-10-29 | 2006-10-10 | Nagoya Industrial Science Research Institute | Metal complex-protein composite and oxidation catalyst |
| US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
| US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
| US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
| EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| WO2006137886A2 (en) * | 2004-09-23 | 2006-12-28 | The Regents Of The University Of California | Assay for vitamin b12 absorption and method of making labeled vitamin b12 |
| US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
| US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
| EP1893038A1 (en) * | 2005-05-17 | 2008-03-05 | Cargill, Incorporated | Granular lecithins, granular lysolecithins, process for their production and compositions containing them |
| JP5475992B2 (ja) * | 2005-08-19 | 2014-04-16 | エンドサイト，インコーポレイテッド | 多剤リガンド結合体 |
| US7774057B2 (en) | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
| DK1965787T3 (da) * | 2005-11-30 | 2013-06-03 | Endo Pharmaceuticals Inc | Behandling af xerostomi med en svovlindeholdende antioxidant |
| US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| WO2008109068A2 (en) | 2007-03-05 | 2008-09-12 | Syracuse University | A conjugate of insulin and vitamin b12 for oral delivery |
| CN101678124A (zh) | 2007-03-14 | 2010-03-24 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
| WO2008115805A2 (en) * | 2007-03-19 | 2008-09-25 | Inflabloc Pharmaceuticals, Inc. | Cobalamin taxane bioconjugates |
| WO2008138646A1 (en) | 2007-05-16 | 2008-11-20 | Ktb Tumorforschungsgesellschaft Mbh | Low-viscous anthracycline formulation |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| EP3569251A1 (en) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| US8164074B2 (en) * | 2007-10-18 | 2012-04-24 | The Invention Science Fund I, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US20090104113A1 (en) * | 2007-10-18 | 2009-04-23 | Searete Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US9557635B2 (en) * | 2007-10-18 | 2017-01-31 | Gearbox, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| GB2453860B (en) | 2007-10-18 | 2011-03-16 | Searete Llc | Ionizing-radiation-responsive compositions,methods and systems |
| US8684898B2 (en) * | 2007-10-18 | 2014-04-01 | The Invention Science Fund I Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8168958B2 (en) * | 2007-10-18 | 2012-05-01 | The Invention Science Fund I, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8227204B2 (en) * | 2007-10-18 | 2012-07-24 | The Invention Science Fund I, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8529426B2 (en) | 2007-10-18 | 2013-09-10 | The Invention Science Fund I Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US20090169484A1 (en) | 2007-12-28 | 2009-07-02 | Ihi Corporation | Iron-salen complex |
| JP2009274962A (ja) * | 2008-05-12 | 2009-11-26 | Yoshihiro Ishikawa | 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 |
| WO2010011662A1 (en) * | 2008-07-21 | 2010-01-28 | Inflabloc Pharmaceuticals, Inc. | Taxane compounds for treating eye disease |
| CN104800195A (zh) | 2008-11-20 | 2015-07-29 | 株式会社Ihi | 自磁性金属salen络合物 |
| WO2011125331A1 (ja) * | 2010-04-06 | 2011-10-13 | 株式会社Ihi | 金属サレン錯体誘導体及びその製造方法 |
| WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
| KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| KR20150070318A (ko) | 2012-10-16 | 2015-06-24 | 엔도사이트, 인코포레이티드 | 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법 |
| WO2014160305A1 (en) * | 2013-03-14 | 2014-10-02 | Albany Molecular Research, Inc. | Ligand-therapeutic agent conjugates and silicon-based linkers |
| EP2983677A4 (en) * | 2013-04-08 | 2016-11-16 | Univ North Carolina | LIGHT-SENSITIVE CONNECTIONS |
| TWI664187B (zh) * | 2013-05-22 | 2019-07-01 | 阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| CN105658230B (zh) * | 2013-08-29 | 2020-04-21 | 希望之城 | 细胞穿透缀合物及其使用方法 |
| GR20130100654A (el) * | 2013-11-22 | 2015-06-18 | Χρηστος Γκολφινου Ταπεινος | Επιφανειακως τροποποιημενα πολλαπλως αποκρινομενα σε ερεθισματα νανο/μικρο-δοχεια ως φορεις φαρμακων για στοχευμενη θεραπεια διαφορων μορφων καρκινου |
| WO2020113130A1 (en) * | 2018-11-29 | 2020-06-04 | The Trustees Of Dartmouth College | Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy |
| GB202018713D0 (en) | 2020-11-27 | 2021-01-13 | Quadram Inst Bioscience | Methods and compositions utilising vitamin b12 binding |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4758421A (en) * | 1985-03-15 | 1988-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Bleomycin conjugates and method |
| NZ217821A (en) | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
| JP3095752B2 (ja) | 1987-07-15 | 2000-10-10 | アメリカ合衆国 | Ｔａｇ‐７２及びヒト癌腫に対して結合特異性を有する第二世代モノクローナル抗体及びその使用方法 |
| US5047227A (en) * | 1988-02-08 | 1991-09-10 | Cytogen Corporation | Novel and improved antibodies for site specific attachment of compounds |
| IL93982A0 (en) * | 1989-04-03 | 1991-01-31 | Purdue Research Foundation | Method for enhancing transmembrane transport of exogenous molecules |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
| KR960702476A (ko) * | 1993-05-20 | 1996-04-27 | 로잘린드 앤 칼도르 | Lhrh 길항제(lhrh antagonists) |
| US5548064A (en) * | 1993-05-24 | 1996-08-20 | Biotech Australia Pty Limited | Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions |
| KR100361075B1 (ko) * | 1994-04-08 | 2003-04-10 | 리셉타겐 코포레이션 | 리셉터조절제및그와관련된방법 |
| US5574018A (en) * | 1994-07-29 | 1996-11-12 | Amgen Inc. | Conjugates of vitamin B12 and proteins |
-
1997
- 1997-08-22 AU AU41482/97A patent/AU738431B2/en not_active Ceased
- 1997-08-22 CA CA2264592A patent/CA2264592C/en not_active Expired - Fee Related
- 1997-08-22 ES ES97939382T patent/ES2244006T3/es not_active Expired - Lifetime
- 1997-08-22 US US09/202,328 patent/US6315978B1/en not_active Expired - Fee Related
- 1997-08-22 WO PCT/US1997/014140 patent/WO1998008859A1/en not_active Ceased
- 1997-08-22 AT AT97939382T patent/ATE298344T1/de active
- 1997-08-22 PT PT97939382T patent/PT1007533E/pt unknown
- 1997-08-22 JP JP10511674A patent/JP2001501596A/ja active Pending
- 1997-08-22 DE DE69733618T patent/DE69733618T2/de not_active Expired - Lifetime
- 1997-08-22 EP EP97939382A patent/EP1007533B1/en not_active Expired - Lifetime
- 1997-08-22 NZ NZ334870A patent/NZ334870A/xx not_active IP Right Cessation
-
2001
- 2001-10-22 US US09/982,940 patent/US6790827B2/en not_active Expired - Lifetime
- 2001-10-22 US US09/982,892 patent/US6776976B2/en not_active Expired - Lifetime
- 2001-10-22 US US09/982,968 patent/US6777237B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU738431B2 (en) | 2001-09-20 |
| CA2264592A1 (en) | 1998-03-05 |
| CA2264592C (en) | 2012-02-21 |
| AU4148297A (en) | 1998-03-19 |
| ATE298344T1 (de) | 2005-07-15 |
| WO1998008859A1 (en) | 1998-03-05 |
| US20020049154A1 (en) | 2002-04-25 |
| US6777237B2 (en) | 2004-08-17 |
| DE69733618D1 (de) | 2005-07-28 |
| US20020111294A1 (en) | 2002-08-15 |
| US6315978B1 (en) | 2001-11-13 |
| EP1007533B1 (en) | 2005-06-22 |
| ES2244006T3 (es) | 2005-12-01 |
| EP1007533A4 (en) | 2002-08-07 |
| DE69733618T2 (de) | 2006-05-11 |
| EP1007533A1 (en) | 2000-06-14 |
| JP2001501596A (ja) | 2001-02-06 |
| US6790827B2 (en) | 2004-09-14 |
| US20020115595A1 (en) | 2002-08-22 |
| US6776976B2 (en) | 2004-08-17 |
| PT1007533E (pt) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334870A (en) | Bioconjugates having a bioactive agent and an organocobalt complex for to specific sites | |
| Haisma et al. | A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer | |
| JP2017128590A (ja) | 抱合方法 | |
| JP6608467B2 (ja) | 生体直交型薬物活性化 | |
| AU3057297A (en) | Targeted combination immunotherapy of cancer | |
| EP0396387A3 (en) | A novel antibody delivery system for biological response modifiers | |
| EP1306095A3 (en) | Methods and compositions for targeting the vasculature of solid tumors | |
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| AU5303700A (en) | Immunoconjugates having high binding affinity | |
| WO1999066951A8 (en) | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | |
| EP2311490A3 (en) | Uses of antibodies to aminophospholipids for cancer treatment | |
| AU7689496A (en) | Design of hormone-like antibodies with agonistic and antagonistic functions | |
| IL147902A0 (en) | C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof | |
| WO1999048536A3 (en) | Delivery of long lasting therapeutic agents by forming covalent attachments in vivo | |
| WO2001005425A3 (en) | Combined preparations comprising daunorubicin derivatives and her2 antibodies | |
| Boschanski et al. | Site-specific conjugation strategy for dual antibody–drug conjugates using aerobic formylglycine-generating enzymes | |
| ZA200408107B (en) | Antibodies derived from anti ed-b l19 and targeting tumor vasculature | |
| Jinno et al. | Epidermal growth factor receptor-dependent cytotoxic effect by an EGF—ribonuclease conjugate on human cancer cell lines-A trial for less immunogenic chimeric toxin- -A trial for less immunogenic chimeric toxin | |
| Ippoliti et al. | Endocytosis of a chimera between human pro‐urokinase and the plant toxin saporin: an unusual internalization mechanism | |
| WO2003009870A1 (en) | Remedies for mammary cancer | |
| WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| WO2002100343A3 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
| WO2004010951A8 (en) | Method of treating tumors | |
| Berki et al. | Novel method for in vitro depletion of T cells by monoclonal antibody-targeted photosensitization | |
| EP1520588A3 (en) | Uses of antibodies to aminophospholipids for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |